Devdatt Kurdikar - 29 May 2025 Form 4 Insider Report for ZIMMER BIOMET HOLDINGS, INC. (ZBH)

Role
Director
Signature
/s/ Matthew R. St. Louis, Attorney-in-Fact for Devdatt Kurdikar (power of attorney previously filed)
Issuer symbol
ZBH
Transactions as of
29 May 2025
Transactions value $
$0
Form type
4
Filing time
02 Jun 2025, 18:48:41 UTC
Previous filing
08 Apr 2025
Next filing
02 Jul 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Kurdikar Devdatt Director 345 E. MAIN STREET, WARSAW /s/ Matthew R. St. Louis, Attorney-in-Fact for Devdatt Kurdikar (power of attorney previously filed) 02 Jun 2025 0001910621

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ZBH Phantom Stock Units Award $0 +810 +159.25% $0.00 1.32K 29 May 2025 Common Stock 810 $92.54 Direct F1, F2, F3, F4
transaction ZBH Restricted Stock Units Award $0 +1.4K $0.00 1.4K 29 May 2025 Common Stock 1.4K Direct F2, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. (the "Company") Deferred Compensation Plan for Non-Employee Directors.
F2 The Conversion or Exercise Price of Derivative Security is 1-for-1.
F3 These units are to be settled in cash in five annual installments commencing within sixty days after the end of the calendar year in which the cessation of the reporting person's service as a Director occurs.
F4 Includes 1.192 phantom stock units accrued on April 30, 2025 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
F5 The Restricted Stock Units are immediately 100% vested and will be subject to mandatory deferral until the later of (1) the reporting person's termination of service as a Director or (2) the date that is three years after the grant date.